NASDAQ:AFMD Affimed (AFMD) Stock Price, News & Analysis $0.90 +0.01 (+1.35%) As of 10:02 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock About Affimed Stock (NASDAQ:AFMD) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Affimed alerts:Sign Up Key Stats Today's Range$0.87▼$0.8950-Day Range$0.57▼$1.0752-Week Range$0.52▼$8.95Volume15,709 shsAverage Volume304,975 shsMarket Capitalization$14.52 millionP/E RatioN/ADividend YieldN/APrice Target$13.50Consensus RatingModerate Buy Company OverviewAffimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States and Germany. The company's lead product candidates include AFM13 that has completed Phase 2 clinical trial for CD30-positive lymphoma, Phase Ib clinical trial for hodgkin lymphoma, and completed Phase IIb clinical study for peripheral T-cell lymphoma; AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase IIa clinical trial for the treatment of advanced cancers; and AFM28, an innate cell engager (ICE), which is in preclinical development for the treatment acute myeloid. It develops AFM32, an ICE candidate that is in preclinical development for the treatment of solid tumors. It has collaboration with Artiva Biotherapeutics to develop the combination of acimtamig and AlloNK; license and strategic collaboration agreement with Roivant Sciences Ltd. to develop and commercialize novel ICE molecules, including AFM32, in oncology; and strategic collaboration agreement with Genentech for the development of certain product candidates, which includes novel NK cell engager-based immunotherapeutics to treat multiple cancers. The company was formerly known as Affimed Therapeutics B.V. and changed its name to Affimed N.V. in October 2014. Affimed N.V. was founded in 2000 and is headquartered in Mannheim, Germany.Read More… Affimed Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks76th Percentile Overall ScoreAFMD MarketRank™: Affimed scored higher than 76% of companies evaluated by MarketBeat, and ranked 212th out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.4 / 5Analyst RatingModerate Buy Consensus RatingAffimed has received a consensus rating of Moderate Buy. The company's average rating score is 2.80, and is based on 4 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageAffimed has received no research coverage in the past 90 days.Read more about Affimed's stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Affimed are expected to grow in the coming year, from ($4.19) to ($2.05) per share.Price to Book Value per Share RatioAffimed has a P/B Ratio of 0.21. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Affimed's valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted4.54% of the float of Affimed has been sold short.Short Interest Ratio / Days to CoverAffimed has a short interest ratio ("days to cover") of 4.4.Change versus previous monthShort interest in Affimed has recently decreased by 1.96%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAffimed does not currently pay a dividend.Dividend GrowthAffimed does not have a long track record of dividend growth. Sustainability and ESG4.3 / 5Environmental Score-1.95 Percentage of Shares Shorted4.54% of the float of Affimed has been sold short.Short Interest Ratio / Days to CoverAffimed has a short interest ratio ("days to cover") of 4.4.Change versus previous monthShort interest in Affimed has recently decreased by 1.96%, indicating that investor sentiment is improving. News and Social Media1.9 / 5News Sentiment0.41 News SentimentAffimed has a news sentiment score of 0.41. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.74 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 14 news articles for Affimed this week, compared to 1 article on an average week.MarketBeat FollowsOnly 2 people have added Affimed to their MarketBeat watchlist in the last 30 days. This is a decrease of -33% compared to the previous 30 days. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Affimed insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 3.80% of the stock of Affimed is held by insiders.Percentage Held by InstitutionsOnly 30.82% of the stock of Affimed is held by institutions.Read more about Affimed's insider trading history. Receive AFMD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Affimed and its competitors with MarketBeat's FREE daily newsletter. Email Address AFMD Stock News HeadlinesStockNews.com Begins Coverage on Affimed (NASDAQ:AFMD)April 25 at 2:11 AM | americanbankingnews.comAffimed Announces Acceptance of Three Abstracts for Presentation at the American Society for ...April 23 at 1:47 PM | gurufocus.comCrypto’s crashing…but we’re still profitingMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess. The news is screaming fear. But while most traders watch their portfolios tank…April 25, 2025 | Crypto Swap Profits (Ad)Affimed Announces Acceptance of Three Abstracts for Presentation at the American Society for ...April 23 at 1:47 PM | gurufocus.comAffimed Announces Acceptance of Three Abstracts for Presentation at the American Society for Clinical Oncology Annual MeetingApril 23 at 10:05 AM | globenewswire.comAffimed receives Nasdaq notice of non-complianceApril 21, 2025 | markets.businessinsider.comAffimed Receives Nasdaq Deficiency Notice Over Low Share Price: Retail’s In Wait-And-Wait ModeApril 21, 2025 | msn.comAffimed Faces Nasdaq Delisting Risk Due to Share PriceApril 21, 2025 | tipranks.comSee More Headlines AFMD Stock Analysis - Frequently Asked Questions How have AFMD shares performed this year? Affimed's stock was trading at $1.19 at the beginning of the year. Since then, AFMD shares have decreased by 25.2% and is now trading at $0.89. View the best growth stocks for 2025 here. How were Affimed's earnings last quarter? Affimed (NASDAQ:AFMD) released its quarterly earnings results on Wednesday, November, 10th. The biopharmaceutical company reported ($1.40) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.30) by $0.10. The biopharmaceutical company had revenue of $10.21 million for the quarter, compared to analysts' expectations of $11.79 million. Affimed had a negative net margin of 7,836.26% and a negative trailing twelve-month return on equity of 193.84%. Read the conference call transcript. When did Affimed's stock split? Affimed shares reverse split before market open on Monday, March 11th 2024. The 1-10 reverse split was announced on Wednesday, March 6th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Friday, March 8th 2024. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. How do I buy shares of Affimed? Shares of AFMD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Affimed own? Based on aggregate information from My MarketBeat watchlists, some other companies that Affimed investors own include Meta Platforms (META), NVIDIA (NVDA), Novavax (NVAX), Tesla (TSLA), Advanced Micro Devices (AMD), Plug Power (PLUG) and Sorrento Therapeutics (SRNE). Company Calendar Last Earnings11/10/2021Today4/25/2025Next Earnings (Estimated)6/11/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:AFMD CIK1608390 Webwww.affimed.com Phone496221674360Fax49-6221-653-0777Employees200Year FoundedN/APrice Target and Rating Average Stock Price Target$13.50 High Stock Price Target$25.00 Low Stock Price Target$4.00 Potential Upside/Downside+1,416.9%Consensus RatingModerate Buy Rating Score (0-4)2.80 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-114,660,000.00 Net Margins-7,836.26% Pretax Margin-7,837.50% Return on Equity-193.84% Return on Assets-107.24% Debt Debt-to-Equity Ratio0.13 Current Ratio1.93 Quick Ratio1.93 Sales & Book Value Annual Sales$877,000.00 Price / Sales16.34 Cash FlowN/A Price / Cash FlowN/A Book Value$4.19 per share Price / Book0.21Miscellaneous Outstanding Shares16,100,000Free Float15,488,000Market Cap$14.33 million OptionableOptionable Beta2.28 Social Links 13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.Get This Free Report This page (NASDAQ:AFMD) was last updated on 4/25/2025 by MarketBeat.com Staff From Our PartnersElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | Sponsored[Action Required] Claim Your FREE IRS Loophole GuideThis shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the ...Colonial Metals | SponsoredFeds Just Admitted It—They Can Take Your CashHere’s the cold truth: If your money is sitting idle in a bank account, it’s vulnerable. That’s why thousan...Priority Gold | SponsoredGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored"I'm risking my reputation on this"I've discovered something so significant about the 2025 crypto market that I had to put everything else aside ...Crypto 101 Media | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Affimed Please log in to your account or sign up in order to add this asset to your watchlist. Share Affimed With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.